DE60126225T2 - Zusammensetzung zur Behandlung von Tumoren oder Krebs, welche Fluorouracil und ein Methylol Übertragungsmittel enthält - Google Patents

Zusammensetzung zur Behandlung von Tumoren oder Krebs, welche Fluorouracil und ein Methylol Übertragungsmittel enthält Download PDF

Info

Publication number
DE60126225T2
DE60126225T2 DE60126225T DE60126225T DE60126225T2 DE 60126225 T2 DE60126225 T2 DE 60126225T2 DE 60126225 T DE60126225 T DE 60126225T DE 60126225 T DE60126225 T DE 60126225T DE 60126225 T2 DE60126225 T2 DE 60126225T2
Authority
DE
Germany
Prior art keywords
transfer agent
taurolidine
methylol transfer
treatment
fluorouracil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60126225T
Other languages
German (de)
English (en)
Other versions
DE60126225D1 (de
Inventor
Paul H. Wilton Redmond
Rolf W. Pfirrmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ed Geistlich Soehne AG fuer Chemische Industrie
Original Assignee
Ed Geistlich Soehne AG fuer Chemische Industrie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ed Geistlich Soehne AG fuer Chemische Industrie filed Critical Ed Geistlich Soehne AG fuer Chemische Industrie
Publication of DE60126225D1 publication Critical patent/DE60126225D1/de
Application granted granted Critical
Publication of DE60126225T2 publication Critical patent/DE60126225T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE60126225T 2000-11-28 2001-11-28 Zusammensetzung zur Behandlung von Tumoren oder Krebs, welche Fluorouracil und ein Methylol Übertragungsmittel enthält Expired - Lifetime DE60126225T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25313800P 2000-11-28 2000-11-28
US253138P 2000-11-28

Publications (2)

Publication Number Publication Date
DE60126225D1 DE60126225D1 (de) 2007-03-15
DE60126225T2 true DE60126225T2 (de) 2007-10-11

Family

ID=22959032

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60126225T Expired - Lifetime DE60126225T2 (de) 2000-11-28 2001-11-28 Zusammensetzung zur Behandlung von Tumoren oder Krebs, welche Fluorouracil und ein Methylol Übertragungsmittel enthält

Country Status (7)

Country Link
US (1) US20020111328A1 (enExample)
EP (1) EP1208840B1 (enExample)
JP (2) JP2002326936A (enExample)
AT (1) ATE352307T1 (enExample)
CA (1) CA2363973C (enExample)
DE (1) DE60126225T2 (enExample)
ES (1) ES2278702T3 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8304390B2 (en) 1997-07-31 2012-11-06 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Method of treatment for preventing or reducing tumor growth in the liver of patient
US20030027818A1 (en) * 2001-04-03 2003-02-06 Redmond H. Paul Treatment of cancers
US20060199811A1 (en) * 1997-07-31 2006-09-07 Pfirrmann Rolf W Method of treatment for preventing or reducing tumor growth in the liver of patient
US20050124608A1 (en) * 2001-04-03 2005-06-09 Redmond H. P. Treatment of cancers
US7345039B2 (en) 1999-06-04 2008-03-18 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Enhancement of effectiveness of 5-fluorouracil in treatment of tumor metastases and cancer
US7892530B2 (en) * 1999-06-04 2011-02-22 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of tumor metastases and cancer
US8030301B2 (en) * 1999-06-04 2011-10-04 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of cancers with methylol-containing compounds and at least one electrolyte
US6753328B2 (en) * 2001-10-01 2004-06-22 Rhode Island Hospital Methods of inhibiting metastases
US20100151004A1 (en) * 2007-03-07 2010-06-17 University Of Medicine And Dentistry Of New Jersey Modulation of drug sensitivity
US20190381060A1 (en) 2016-01-11 2019-12-19 Cormedix Inc. Taurolidine treatment for myc-expressing tumors in mammalian bodies
CN113347976A (zh) * 2018-08-28 2021-09-03 科医公司 用牛磺罗定水解产物进行的神经母细胞瘤治疗

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9015108D0 (en) * 1990-07-09 1990-08-29 Geistlich Soehne Ag Chemical compositions
GB9716219D0 (en) * 1997-07-31 1997-10-08 Geistlich Soehne Ag Prevention of metastases
US6479481B1 (en) * 1999-06-04 2002-11-12 Ed. Geistlich Soehne Ag Fur Chemische Industrie Methods and compositions for treating primary and secondary tumors of the central nervous system (CNS)

Also Published As

Publication number Publication date
JP2010043115A (ja) 2010-02-25
JP2002326936A (ja) 2002-11-15
CA2363973A1 (en) 2002-05-28
ATE352307T1 (de) 2007-02-15
DE60126225D1 (de) 2007-03-15
ES2278702T3 (es) 2007-08-16
US20020111328A1 (en) 2002-08-15
CA2363973C (en) 2009-03-10
EP1208840A2 (en) 2002-05-29
EP1208840B1 (en) 2007-01-24
EP1208840A3 (en) 2003-05-21

Similar Documents

Publication Publication Date Title
Von Hoff et al. Phase I clinical investigation of 1, 4-dihydroxy-5, 8-bis {{{2-[(2-hydroxyethyl) amino] ethyl} amino}}-9, 10-anthracenedione dihydrochloride (NSC 301739), a new anthracenedione
DE60103453T2 (de) Verwendung von albuminstabilisiertem Paclitaxel zur Herstellung eines Arzneimittels zum Behandeln von festen Tumoren und das so erhaltene Arzneimittel
DE60011391T2 (de) Verfahren und zusammensetzungen zur erhöhung der anzahl weisser blutzellen
EP0864327B1 (de) Verwendung von Pyrimidinderivaten zur Herstellung eines Arzneimittels zur Prävention von Krebs
DE60036826T2 (de) Verwendung von et743 in kombinationstherapie mit dexamethason zur behandlung von krebs
DE60004348T2 (de) Kombinierte vorbereitungen, die morpholin anthracyclin und platin derivate
DE60126225T2 (de) Zusammensetzung zur Behandlung von Tumoren oder Krebs, welche Fluorouracil und ein Methylol Übertragungsmittel enthält
Hellmann et al. Preliminary clinical assessment of ICRF 159 in acute leukaemia and lymphosarcoma
EP0986378A1 (en) Phorbol esters as anti-neoplastic agents
JPH05500973A (ja) 化学的組成物
DE3319347A1 (de) Arzneimittel zur verstaerkung der therapeutischen wirkung von antitumormitteln und deren verwendung
JPH0296524A (ja) 抗癌活性を有する治療薬組成物と癌の治療方法
JPH06505231A (ja) 癌またはエイズの治療におけるキノンの使用
Coleman et al. Initial pharmacology and toxicology of intravenous desmethylmisonidazole
DE69103908T2 (de) Verbessertes behandlungsverfahren für krebs.
EP2301551A1 (de) Anwendung von Alkylphosphocholinen in kombination mit Antitumormedikamenten
DE3619426A1 (de) Mittel zur erhoehung der widerstandskraft gegen erkaeltungskrankheiten bei patienten mit eingeschraenkter lungenfunktion
DE69408394T2 (de) 4-Piperidino-piperidin zur Behandlung von Tumoren
EP4335442A1 (en) Use of adenosine diphosphate ribose as adjuvant therapy for radiation and/or anticancer therapy
DE2428409C3 (de) S3'-Bis-(3-hydroxy-4-hydroxymethyl-2-methyl-5-pyridylmethyl)-carbonodithioat, dessen pharmakologisch verträgliche Salze und Arzneimittel
WO2005040045A2 (de) Verfahren zur herstellung von trans- oder cis-diammoniumdichlorodihydroxoplatin (iv) -salzen und ­-derivaten und ihre verwendung zur herstellung von pharmazeutischen wirkstoffen
DE69007439T2 (de) Mittel gegen Tumore.
Handschumacher et al. Pharmacological and clinical studies with triacetyl 6-azauridine
US3222253A (en) Antimitotic colchicines
WO2000010543A2 (de) Arzneimittel enthaltend platinkomplexverbindungen sowie deren verwendung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition